The alteration of fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo?
暂无分享,去创建一个
K. Okumura | H. Yagita | Y. Nakajima | M. Nagao | H. Kanehiro | M. Hisanaga | S. Ko | Y. Aomatsu | N. Kayagaki | H. Nakano | Takatsugu Yamada
[1] C. Brady,et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. , 1998, Journal of immunology.
[2] P. Hainaut,et al. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. , 1998, Cancer research.
[3] Matsunaga,et al. Elevated serum levels of soluble Fas/APO‐1 (CD95) in patients with hepatocellular carcinoma , 1998, Clinical and experimental immunology.
[4] K. Isselbacher,et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[5] D. Green,et al. Human lung carcinomas express Fas ligand. , 1997, Cancer research.
[6] T. Koike,et al. Serum levels of soluble Fas/APO‐1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases , 1997, Clinical and experimental immunology.
[7] P. Galle,et al. Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.
[8] S. Nagata. Fas ligand and immune evasion , 1996, Nature Medicine.
[9] J. Tschopp,et al. Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.
[10] L. Owen-Schaub,et al. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. , 1996, Cancer research.
[11] F. Shanahan,et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.
[12] W. Hong,et al. Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.
[13] M. Mizumoto,et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential , 1996, Hepatology.
[14] M. Kojiro,et al. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. , 1996, American Journal of Pathology.
[15] A. H. Drummond,et al. Fas ligand in human serum , 1996, Nature Medicine.
[16] D. Green,et al. Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.
[17] P. Galle,et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage , 1995, The Journal of experimental medicine.
[18] M. Peter,et al. APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. , 1995, International immunology.
[19] D. Bellgrau,et al. A role for CD95 ligand in preventing graft rejection , 1995, Nature.
[20] J. Mountz,et al. Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. , 1995, The Biochemical journal.
[21] C. Ware,et al. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? , 1995, Cancer letters.
[22] M. Weller,et al. Fas/APO-1 gene transfer for human malignant glioma. , 1995, Cancer research.
[23] J. Roth,et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression , 1995, Molecular and cellular biology.
[24] G. Fiucci,et al. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. , 1995, Journal of immunology.
[25] S. Nagata,et al. The Fas death factor , 1995, Science.
[26] P. Krammer,et al. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) , 1995, Nature.
[27] S. Ju,et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.
[28] Seamus J. Martin,et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas , 1995, Nature.
[29] C. Smith,et al. Fas ligand mediates activation-induced cell death in human T lymphocytes , 1995, The Journal of experimental medicine.
[30] J. Tschopp,et al. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways , 1994, Nature.
[31] V. Zurawski,et al. Apoptotic cell death induced by a mouse‐human anti‐APO‐1 chimeric antibody leads to tumor regression , 1994, International journal of cancer.
[32] H Hengartner,et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.
[33] S. Yonehara,et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[34] S. Ju,et al. Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[35] K. Koretz,et al. Expression of APO‐1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium , 1994, International journal of cancer.
[36] I. Behrmann,et al. Regulation of apoptosis in the immune system. , 1994, Current opinion in immunology.
[37] Matthew J. Brauer,et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.
[38] L. Owen-Schaub,et al. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. , 1994, Cancer research.
[39] P. Erb,et al. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. , 1994, Journal of immunology.
[40] Takashi Suda,et al. Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.
[41] S. Nagata,et al. Lethal effect of the anti-Fas antibody in mice , 1993, Nature.
[42] P. Golstein,et al. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity , 1993, The Journal of experimental medicine.
[43] M. Pawlita,et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. , 1992, The Journal of biological chemistry.
[44] Atsushi Hase,et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.
[45] P. Möller,et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. , 1989, Science.
[46] S. Yonehara,et al. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor , 1989, The Journal of experimental medicine.
[47] K. Koretz,et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. , 1993, Laboratory investigation; a journal of technical methods and pathology.